ConductScience.org, home

Paper41900829

Self-Assembled Gefitinib Nanosuspension Prepared via Hummer Acoustic Resonance Technology: Enhanced Dissolution, In Vitro Anticancer Activity and Long-Term Stability.

Wu HL and 9 others. Pharmaceutics, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Self-Assembled Gefitinib Nanosuspension Prepared via Hummer Acoustic Resonance Technology: Enhanced Dissolution, In Vitro Anticancer Activity and Long-Term Stability. Papers, record 41900829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41900829

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Self-Assembled Gefitinib Nanosuspension Prepared via Hummer Acoustic Resonance Technology: Enhanced Dissolution, In Vitro Anticancer Activity and Long-Term Stability.
PubMed
Journal
Pharmaceutics
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wu HLHai-Li
2Wen RYRu-Yan
3Chen LLing
4Hu ZLZhen-Long
5Qin BYBao-Yi
6Chen JFJie-Feng
7Liu MHMeng-Hua
8Huang XQXuan-Qi
9Lin NNinghttps://orcid.org/0000-0002-6086-6661
10Chen QQinghttps://orcid.org/0000-0003-1709-8131

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
22161009National Natural Science Foundation of ChinaPubMed
2025GXNFAA069355Guangxi Science and Technology ProgramPubMed
202408Guangxi University of Chinese Medicine "Qihuang Project" High-level Talent Team Cul-tivation ProgrammePubMed
2022C014Gui Style Xinglin Top Talent Funding Project of Guangxi University of Chinese MedicinePubMed

Source PubMed

Download CSV of grants

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139817679Cancer statistics, 2025.CA Cancer J Clin2025https://conductscience.org/library/papers/39817679PubMed
232243963Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor.Int J Pharm2020https://conductscience.org/library/papers/32243963PubMed
339861782Nanosuspension Innovations: Expanding Horizons in Drug Delivery Techniques.Pharmaceutics2025https://conductscience.org/library/papers/39861782PubMed
431969986Emerging role of nanosuspensions in drug delivery systems.Biomater Res2020https://conductscience.org/library/papers/31969986PubMed
537567370The first nano-cocrystal formulation of marine drug cytarabine with uracil based on cocrystal nanonization strategy for long-acting injection exhibiting enhanced antitumor activity.Int J Pharm2023https://conductscience.org/library/papers/37567370PubMed
639930276Unveiling the Potential of Nanosuspension Formulation Strategy for Improved Oral Bioavailability of Gefitinib.AAPS PharmSciTech2025https://conductscience.org/library/papers/39930276PubMed
737765182Do Mixtures of Beads with Different Sizes Improve Wet Stirred Media Milling of Drug Suspensions?Pharmaceutics2023https://conductscience.org/library/papers/37765182PubMed
822160570Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Mol Biol Rep2012https://conductscience.org/library/papers/22160570PubMed
939953594Carrier-free nanoparticles-new strategy of improving druggability of natural products.J Nanobiotechnology2025https://conductscience.org/library/papers/39953594PubMed
1023954372Stability of nanosuspensions in drug delivery.J Control Release2013https://conductscience.org/library/papers/23954372PubMed
1139477136Spring and parachute approach for piroxicam dissolution; its phenomenological model on the thermodynamics of irreversible processes.Int J Pharm2024https://conductscience.org/library/papers/39477136PubMed
1234984564Solid Dispersions of Gefitinib Prepared by Spray Drying with Improved Mucoadhesive and Drug Dissolution Properties.AAPS PharmSciTech2022https://conductscience.org/library/papers/34984564PubMed
1337627812Systematic Screening Study for the Selection of Proper Stabilizers to Produce Physically Stable Canagliflozin Nanosuspension by Wet Milling Method.Bioengineering (Basel)2023https://conductscience.org/library/papers/37627812PubMed
1428315464A novel nanosuspension of andrographolide: Preparation, characterization and passive liver target evaluation in rats.Eur J Pharm Sci2017https://conductscience.org/library/papers/28315464PubMed
1537242763Formulation Strategies of Nanosuspensions for Various Administration Routes.Pharmaceutics2023https://conductscience.org/library/papers/37242763PubMed
1620600732Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability.Int J Pharm2010https://conductscience.org/library/papers/20600732PubMed
1738168678Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression.Biomater Sci2024https://conductscience.org/library/papers/38168678PubMed
1836436741Highly water-soluble dapsone nanocrystals: Towards innovative preparations for an undermined drug.Int J Pharm2023https://conductscience.org/library/papers/36436741PubMed
1939586510Preparation and characterization of andrographolide nano-cocrystals using hummer acoustic resonance technology.Int J Pharm2025https://conductscience.org/library/papers/39586510PubMed
2039370058Acoustic resonance technology and quality by design approach facilitate the development of the robust tetrandrine nano-delivery system.Eur J Pharm Biopharm2024https://conductscience.org/library/papers/39370058PubMed

See all 30 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42198266Development and In Vitro Evaluation of Gefitinib-Salicylic Acid Nanocrystals for Improved Bioavailability.Pharmaceutics2026https://conductscience.org/library/papers/42198266

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41900829

GET https://conductscience.org/api/papers/v1/41900829/references?page=2